Search academic texts

Information × Registration Number 0221U101553, 0118U003210 , R & D reports Title To develop a complex treatment program for patients with secondary edematous breast cancer with researh of the mechanisms of pathogenesis of inflammatory and edematous components of aggressiveness of tumor process popup.stage_title Head Krasnoselskiy Mikola V., Доктор медичних наук Registration Date 22-01-2021 Organization State Organization "Grigoriev Institute for Medical Radiologiy and Oncology of the National Academy of Medical Sciences of Ukraine" popup.description2 Object of study: secondary-edematous breast cancer (SEBC) with different expression profile of diagnostic and prognostic markers of tumor, inflammation and edema. The aim: to increase the effectiveness of complex treatment of patients with SEBC by personalizing on the basis of determining the role of inflammatory and edematous processes. Research methods and techniques: clinical and instrumental, biochemical, morphological, immunohistochemical, statistical. Theoretical and practical results: an algorithm was developed to determine the severity of perifocal edema in patients with SEBC according to MRI, which allowed to assess the severity of perifocal edema of breast skin, its parenchyma and tumor, reduce treatment time, aggressiveness of neoadjuvant chemotherapy. It is recommended that if the VEGF / IL-6 ratio is greater than 1.3, long-term anti-inflammatory therapy with neoadjuvant chemotherapy is included. Use of the anti-inflammatory drug "Ranselex" in neoadjuvant treatment of patients with SEBC increases the overall and non-recurrent survival of patients. Novelty: for the first time a set of informative indicators was developed, which allows to differentiate the inflammatory process and personalize the complex treatment of patients. It is proved that in most patients with SEBC before neoadjuvant therapy there is an increased content of pro- and anti-inflammatory cytokines, as well as VEGF, NF-kβ, which indicates the aggressiveness of the tumor process and the severity of the inflammatory component. For the first time, the relationship between the concentration of VEGF, IL-6, their ratio and the objective response to treatment (by degree of regression) was determined, which assessed the direct effect of neoadjuvant therapy in patients with SEBC. The effectiveness of implementation: the efficiency of complex therapy of patients with SEBC was increased from 86.5% to 93.8% (overall 2-year survival). Area of application: oncology.  Product Description popup.authors Bilyi Oleksandr M. Balaka Svyatoslav M. Grebinyk Lidiya V. Esipova Nataliia M. Kantsedal Olena M. Kondrashova Olena I. Lukashkova Olha P. Miroshnychenko Mykhailo S. Mitryaeva Nataliya A. Movchan Oleksii V. Nasonova Alla M. Pilipenko Sergiy O Ponomarov Ihor M. Potapova Tetiana I. Radchenko Oleksandr A. Revenkova Svitlana I. Slobodianiuk Olha V. Sorokina Iryna V Teslenko Iryna M. Tkachenko Yurii H Shutov Serhii V Yakovtsova Iryna I. popup.nrat_date 2021-01-22 Close